Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
696 daily bars · split adjusted
Current price $0.0001
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 42.28 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 33.33 | Oscillator | Neutral |
| Williams %R (14) | -100.00 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.00 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 14.56 (+DI 15.6 / -DI 20.7) | Trend | Neutral |
| EMA 20 | 0.00 | MA | Strong Sell |
| SMA 20 | 0.00 | MA | Strong Sell |
| EMA 50 | 0.00 | MA | Strong Sell |
| SMA 50 | 0.00 | MA | Strong Sell |
| SMA 200 | 0.00 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Dec 31, 07 | Severson Mark A | officer: Chief Financial Officer | 0 | — | |
| Dec 31, 07 | Severson Mark A | officer: Chief Financial Officer | D | 0 | — |
| Dec 31, 07 | Severson Mark A | officer: Chief Financial Officer | 0 | — | |
| Dec 31, 07 | Severson Mark A | officer: Chief Financial Officer | I | 0 | — |
| Oct 1, 07 | Severson Mark A | officer | 0 | — | |
| Mar 31, 07 | Severson Mark A | officer: Chief Financial Officer | J-Other | 312 @ $12.40 | $3.87K |
| Mar 20, 07 | Severson Mark A | officer: Chief Financial Officer | I-Discretionary | 997 @ $12.48 | $12.44K |
| Jan 31, 07 | Severson Mark A | officer: Chief Financial Officer | P-Purchase | 1,000 @ $12.25 | $12.25K |
Stock news · updated daily
Acquisition expands Fifty 1 Labs' portfolio with a five-product musculoskeletal recovery platform focused on injury recovery, rehabilitation, connective tissue support, joint health, and peptide-focused research VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY), an emerging biotechnology and health innovation company focused on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness, today announced that it has acquired a musculoskeletal recovery product line from MSK Signal, a Canadian Biotech Company. The acquired product line includes five key product concepts designed to support Fifty 1 Labs' growth strategy in the peptide and musculoskeletal health markets.
Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient support VANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Nov 14, 2025 | — | 0.00 | — | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 1-A | Aug 10, 2026 | 2026-08-10 09:12:47 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | FITY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.5x | -3447.7x · sector 20.7x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | -0.1x | -51.8x | Discount |
| Price / Sales | 1216.8x | 64592.8x | Discount |
| EV / EBITDA | -1.3x | -3471.8x | Discount |
| Return on equity | 72.7% | — | Top tier |
| Gross margin | 0.0% | 25.4% | Below hist. |
| Debt / Equity | -0.21 | -0.61 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -1,496.29 | Distress |
Discounted cash flow model